Regulus Announces Timing for Fourth Quarter and Year-End 2013 Financial Results Webcast and Conference Call

   Regulus Announces Timing for Fourth Quarter and Year-End 2013 Financial
                     Results Webcast and Conference Call

PR Newswire

LA JOLLA, Calif., Feb. 20, 2014

LA JOLLA, Calif., Feb. 20, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
(NASDAQ:RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, today announced that
it will report financial results and highlights for the fourth quarter and
year ended December 31, 2013 on Thursday, February 27, 2014, after the U.S.
financial markets close.

Regulus will host a conference call and webcast on Thursday, February 27, 2014
at 5:00 pm Eastern Standard Time to discuss its fourth quarter and year-end
2013 financial results, recent company highlights and its expectations for
2014. A live webcast of the call will be available online at
www.regulusrx.com. To access the call, please dial (877) 257-8599 (domestic)
or (970) 315-0459 (international) and refer to conference ID 2177234. To
access the telephone replay of the call, dial (855) 859-2056 (domestic) or
(404) 537-3406 (international), passcode 2177234. The webcast and telephone
replay will be archived on the company's website following the call.

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting
microRNAs.Regulus is uniquely positioned to leverage a mature therapeutic
platform that harnesses the oligonucleotide drug discovery and development
expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.,
which founded the company. Regulus has a well-balanced microRNA therapeutic
pipeline entering clinical development, an emerging microRNA biomarkers
platform to support its therapeutic programs, and a rich intellectual property
estate to retain its leadership in the microRNA field. Regulus intends to
focus its proprietary efforts on developing microRNA therapeutics for oncology
indications and orphan diseases and is currently advancing several programs
toward clinical development in oncology, fibrosis and metabolic diseases.
Specifically, Regulus is developing RG-012 for the treatment of Alport
Syndrome, a life-threatening genetic disease with no approved therapy, and
RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment
of chronic hepatitis C virus infection. Regulus' commitment to innovation and
its leadership in the microRNA field have enabled the formation of strategic
alliances with AstraZeneca, GlaxoSmithKline and Sanofi. In addition, the
Company has established Regulus microMarkers™, a research and development
division focused on identifying microRNAs as biomarkers of human disease,
which is designed to support its therapeutic pipeline, collaborators and
strategic partners.

For more information, please visithttp://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Website: http://www.regulusrx.com
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., 858-202-6321, aconrad@regulusrx.com
or Media: Liz Bryan, Spectrum Science, lbryan@spectrumscience.com,
202-955-6222 x2526
 
Press spacebar to pause and continue. Press esc to stop.